Consistent with the higher efficiency of DMT-1 relative to ferritin coupled with iron, in vivo results in glioma cells implanted in mice confirmed a bright contrast was sustained relative to control cells beyond 24 h. This evidence concerns the gene SLC11A2 and glioma.